fashion -WSS

fashion

author：focus 2025-09-29 01:36:04 - browse：85449

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： New rules on organ donation and transplantation 'will bring chaos'

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

Why Sanofi got shellacked over its spinoff

Providers still hesitate to prescribe buprenorphine, study finds

7 of the most gruesome medical devices in history

Readout Newsletter: New research from Sanofi, Regeneron, etc.

White House launches permanent pandemic office

explore

fashion

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: XBI biotech index, Akero Therapeutics

Psychedelics group wrestles with new pharma identity

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: What happened with Sarepta's Duchenne data

Virginia high school admissions case could be legal follow

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Apple is now the first public company to be valued at $3 trillion

Diversifying clinical trials isn't enough to close racial gaps: study

knowledge

Chimpanzees, like humans and whales, get menopause: Study

As Taiwan prepares for anti

Emergency medicine has repudiated 'excited delirium.' Now what?

Eli Lilly to pay $200M for Beam’s stake in gene

First Opinion Podcast: How to protect health care in times of war

Caitlin Bernard's story shows physicians can't shy from advocacy

focus

explore

knowledge

explore